Applied Molecular Evolution Announces Positive Rulings in Kauffman Patent Litigation.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Applied Molecular Evolution (AME See AIT. ) today announced that it has recently received positive rulings in patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. cases related to the Kauffman family of patents. On Wednesday, October 8, 2004, the district judge presiding over AME's pending legal action against MorphoSys for infringement of the Kauffman family of patents issued an order denying all summary judgment motions filed by MorphoSys and AME. A magistrate judge had recommended on January 6, 2003, that the district court judge grant the MorphoSys motion for non-infringement and deny all other motions. The district court judge declined to accept the magistrate judge's recommendation. Background: on June 25, 2001, Applied Molecular Evolution (AME) filed a complaint against MorphoSys AG, a company focused on the discovery and development of human antibodies, in the United States District Court United States District Court In the U.S., any of the 94 trial courts of general jurisdiction in the federal judicial system. Each state, as well as the District of Columbia and the Commonwealth of Puerto Rico, has at least one federal district court. of Massachusetts seeking damages for infringement of five United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patents originally issued to Dr. Stuart Kauffman. Further, on November 8, 2004, AME successfully defended oppositions filed by MorphoSys, Archemix, and SomaLogic against specific claims in a corresponding Kauffman patent issued in Europe. "These legal decisions and the recent successful defense of the Kauffman patents in Europe remove the uncertainty regarding this patent estate caused by ongoing litigation. We continue to believe this technology is fundamental to the directed evolution approach for bioproduct development. AME is therefore committed to making the technology accessible and believes the judge's denial of summary judgment in the MorphoSys case and the recent ruling by the European Patent Office may have a positive influence on our licensing program," commented William D. Huse, M.D., Ph.D., President of AME. Inquiries regarding licensing can be directed to AME. About AME AME is a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. and a leader in applying directed molecular evolution to improve healthcare by optimizing and developing human biotherapeutics. Directed molecular evolution is a process for optimizing genes and proteins for specific commercial purposes. Since its inception, AME's principal focus has been on applying its proprietary AMEsystem(TM) technology platform to human biotherapeutics, the largest market for directed molecular evolution. Biotherapeutics, or biopharmaceuticals, are protein pharmaceuticals such as antibodies, cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , hormones and enzymes. AME uses its proprietary technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion